Drugs / Cerebrolyisin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06897176 | Mar → Jun 2025 overdue | stroke disorder | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cerebrolyisin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06897176 ↗ |
| Action | Activate | “Cerebrolysin activates the same PI3K/Akt pathway as BDNF” NCT06897176 ↗ |
| Route | Intravenous | “Cerebrolysin is administered via intravenous injection” NCT06897176 ↗ |